Literature DB >> 21160052

A mouse model of airway disease: oncostatin M-induced pulmonary eosinophilia, goblet cell hyperplasia, and airway hyperresponsiveness are STAT6 dependent, and interstitial pulmonary fibrosis is STAT6 independent.

Dominik K Fritz1, Christine Kerr, Ramzi Fattouh, Alba Llop-Guevara, Waliul I Khan, Manel Jordana, Carl D Richards.   

Abstract

Oncostatin M (OSM), a pleiotropic cytokine of the gp130 cytokine family, has been implicated in chronic allergic inflammatory and fibrotic disease states associated with tissue eosinophilia. Mouse (m)OSM induces airway eosinophilic inflammation and interstitial pulmonary fibrosis in vivo and regulates STAT6 activation in vitro. To determine the requirement of STAT6 in OSM-induced effects in vivo, we examined wild-type (WT) and STAT6-knockout (STAT6(-/-)) C57BL/6 mouse lung responses to transient ectopic overexpression of mOSM using an adenoviral vector (AdmOSM). Intratracheal AdmOSM elicited persistent eosinophilic lung inflammation that was abolished in STAT6(-/-) mice. AdmOSM also induced pronounced pulmonary remodeling characterized by goblet cell hyperplasia and parenchymal interstitial fibrosis. Goblet cell hyperplasia was STAT6 dependent; however, parenchymal interstitial fibrosis was not. OSM also induced airway hyperresponsiveness in WT mice that was abolished in STAT6(-/-) mice. OSM stimulated an inflammatory signature in the lungs of WT mice that demonstrated STAT6-dependent regulation of Th2 cytokines (IL-4, IL-13), chemokines (eotaxin-1/2, MCP-1, keratinocyte chemoattractant), and extracellular matrix modulators (tissue inhibitor of matrix metalloproteinase-1, matrix metalloproteinase-13), but STAT6-independent regulation of IL-4Rα, total lung collagen, collagen-1A1, -1A2 mRNA, and parenchymal collagen and α smooth muscle actin accumulation. Thus, overexpression of mOSM induces STAT6-dependent pulmonary eosinophilia, mucous/goblet cell hyperplasia, and airway hyperresponsiveness but STAT6-independent mechanisms of lung tissue extracellular matrix accumulation. These results also suggest that eosinophil or neutrophil accumulation in mouse lungs is not required for OSM-induced lung parenchymal collagen deposition and that OSM may have unique roles in the pathogenesis of allergic and fibrotic lung disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21160052     DOI: 10.4049/jimmunol.0903476

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Prenatal secondhand cigarette smoke promotes Th2 polarization and impairs goblet cell differentiation and airway mucus formation.

Authors:  Shashi P Singh; Sravanthi Gundavarapu; Juan C Peña-Philippides; Jules Rir-Sima-ah; Neerad C Mishra; Julie A Wilder; Raymond J Langley; Kevin R Smith; Mohan L Sopori
Journal:  J Immunol       Date:  2011-09-19       Impact factor: 5.422

2.  Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease.

Authors:  Kathryn L Pothoven; James E Norton; Kathryn E Hulse; Lydia A Suh; Roderick G Carter; Erin Rocci; Kathleen E Harris; Stephanie Shintani-Smith; David B Conley; Rakesh K Chandra; Mark C Liu; Atsushi Kato; Nirmala Gonsalves; Leslie C Grammer; Anju T Peters; Robert C Kern; Paul J Bryce; Bruce K Tan; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2015-04-01       Impact factor: 10.793

Review 3.  The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease.

Authors:  Kathryn L Pothoven; Robert P Schleimer
Journal:  Tissue Barriers       Date:  2017-06-13

4.  Role of oncostatin M in the pathogenesis of vernal keratoconjunctivitis: focus on tissue remodeling.

Authors:  Keitaro Mashimo; Ayumi Usui-Ouchi; Yousuke Ito; Rei Wakasa-Arai; Norihiko Yokoi; Satoshi Kawasaki; Akira Murakami; Akira Matsuda; Nobuyuki Ebihara
Journal:  Jpn J Ophthalmol       Date:  2021-01-06       Impact factor: 2.447

5.  Fibulin-1c regulates transforming growth factor-β activation in pulmonary tissue fibrosis.

Authors:  Gang Liu; Marion A Cooley; Andrew G Jarnicki; Theo Borghuis; Prema M Nair; Gavin Tjin; Alan C Hsu; Tatt Jhong Haw; Michael Fricker; Celeste L Harrison; Bernadette Jones; Nicole G Hansbro; Peter A Wark; Jay C Horvat; W Scott Argraves; Brian G Oliver; Darryl A Knight; Janette K Burgess; Philip M Hansbro
Journal:  JCI Insight       Date:  2019-07-25

6.  Fstl1 Promotes Asthmatic Airway Remodeling by Inducing Oncostatin M.

Authors:  Marina Miller; Andrew Beppu; Peter Rosenthal; Alexa Pham; Sudipta Das; Maya Karta; Dae Jin Song; Christine Vuong; Taylor Doherty; Michael Croft; Bruce Zuraw; Xu Zhang; Xiang Gao; Seema Aceves; Fazila Chouiali; Qutayba Hamid; David H Broide
Journal:  J Immunol       Date:  2015-09-09       Impact factor: 5.422

7.  Oncostatin M and its role in fibrosis.

Authors:  Lukasz Stawski; Maria Trojanowska
Journal:  Connect Tissue Res       Date:  2018-07-30       Impact factor: 3.417

8.  Pulmonary expression of oncostatin M (OSM) promotes inducible BALT formation independently of IL-6, despite a role for IL-6 in OSM-driven pulmonary inflammation.

Authors:  Fernando M Botelho; Javier Rangel-Moreno; Dominik Fritz; Troy D Randall; Zhou Xing; Carl D Richards
Journal:  J Immunol       Date:  2013-06-24       Impact factor: 5.422

9.  Association of variants in innate immune genes with asthma and eczema.

Authors:  Sunita Sharma; Audrey Poon; Blanca E Himes; Jessica Lasky-Su; Joanne E Sordillo; Kathleen Belanger; Donald K Milton; Michael B Bracken; Elizabeth W Triche; Brian P Leaderer; Diane R Gold; Augusto A Litonjua
Journal:  Pediatr Allergy Immunol       Date:  2011-12-23       Impact factor: 6.377

10.  Oncostatin M overexpression induces matrix deposition, STAT3 activation, and SMAD1 Dysregulation in lungs of fibrosis-resistant BALB/c mice.

Authors:  Steven Wong; Fernando M Botelho; Rebecca M Rodrigues; Carl D Richards
Journal:  Lab Invest       Date:  2014-06-16       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.